Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ROQ.L
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.01
vs -0.01
Q2.23
N/A
-0.01
vs -0.02
Q4.23
N/A
-0.01
vs -0.01
Q2.24
N/A
-0.00
vs -0.01
Sales Growth
YoY
Current
Estimates
Q4.22
-100%
NA vs 719
Q2.23
NA
200K vs NA
Q4.23
NA
NA vs NA
Q2.24
-99%
2.7K vs 200K
Return on Equity
QoQ
Q2.21
-34%
-0.34
vs -0.13
Q4.21
-15%
-0.15
vs -0.34
Q2.22
-23%
-0.23
vs -0.15
Q4.22
-12%
-0.12
vs -0.23
Q2.23
-12%
-0.12
vs -0.12
Q4.23
-17%
-0.17
vs -0.12
Q2.24
-12%
-0.12
vs -0.17
Institutionnal Ownership
Relative Strength
ROQ.L
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
LSE
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.15Â ( -9.48%)
Pre-market NaN$
0.00 (0.00%)
Relative Strenght
Volume Buzz
-73%
Earning Acce
No
Dist 52w H.
79%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ROQ.L compares to sector?
ROQ.L
-1x